Sanofi

Sanofi-a Ventis Deutschland Gmbh

Sagentia Limited

Sanofi-aventis

Aventis Pharma Deutschland, Gmbh

Dieter Kadereit

Matthias Schaefer

Andreas W Herling

Thomas Klabunde

Elisabeth Defossa

Karl-Ulrich Wendt

Karl Schoenafinger

Michael Wagner

Andreas Evers

Thomas Huebschle

Stephanie Hachtel

Katrin Hiss

Torsten Haack

Martin Bossart

Hans-Joerg Burger

Erich Von Roedern

Siegfried Stengelin

Oliver Plettenburg

Katrin Lorenz

Armin Hofmeister

Sven Ruf

Axel Dietrich

Kurt Ritter

Werngard Czechtizky

Bernd Henkel

Martin Lorenz

Matthias Loehn

Heiner Glombik

Hartmut Strobel

Matthias Gossel

Josef Pernerstorfer

Lothar Schwink

Alfons Enhsen

Marcel Patek

Alena Safarova

Aleksandra Weichsel

L Charlie Chen

Joachim Brendel

Pradeep K Dhal

Stefan Peukert

James E Stefano

Christian Buning

Nis Halland

Matthias Schafer

Aimo Kannt

Dieter Schmoll

Thomas Olpp

Matthias Lohmann

Nino Meyer

Christoph Pöverlein

Peter Monecke

Paul Konowicz

Andreas Gille

Michael Schabbach

Hubert Heuer

Alexander David Norman

Jean-Michel Altenburger

Congyi Huang

Harald Berchtold

Norbert Nagel

Bruno Baumgartner

Timothy Charles Frearson

Stefania Pfeiffer-Marek

Harm Brummerhop

Yuri Ivashchenko

Simon Gessler

Matthias Dreyer

Charlotte Emma Harvey

Mandy Mohnicke

Peyman Sakhaii

Joachim Tillner

Nils Poth

Matthias Urmann

Paulus Wohlfart

Thomas Maier

Joerg Rieke-Zapp

Philip Janiak

Alexander Schiffer

Ralf Elvert

Matthias Löhn

Markus Kohlmann

Silke Haag-Diergarten

Bruno Poirier

Robert Miller

Magnus Besev

Véronique Briand

Sabine Gratzer

Elisabeth DeFossa

Ashfaq Parkar

Thomas Kalbunde

Andrea Heiberger

Claus Geiger

Susanne Kilp

Veronique Briand

The disclosure refers to a device, for example a cartridge, a syringe or an autoinjector, which reduces the possibility of user error and provides an easy and automatic operation during mixing and/or reconstitution. The device is adapted such that activation of the device causes movement one of a first piston and a second piston in second chamber in an axial direction of the device, thereby moving the other one of the first piston and the second piston into the same axial direction of the device, opening a fluid communication path between the second chamber and a first chamber of the device, and expelling a second material from the second chamber into the first chamber via the fluid communication path. The disclosure is further directed to a respective mixing and/or reconstitution method.

Device and mixing and/or reconstitution method

A mixing and/or reconstitution system reduces the possibility of user error and provides a well mixed and/or reconstituted drug in a short time. The system comprises a device containing a first material within a first chamber, a housing, and a plunger, the plunger comprising a second chamber containing a second material, wherein one of the first and the second material is a fluid, and a movable element with an electric, magnetic, or paramagnetic characteristic, wherein the second chamber is initially closed; and a base unit comprising a recess for accommodation of the device, a control unit, and an electromagnetic unit which is adapted to produce an electromagnetic field penetrating the recess, wherein the control unit can electrically operate the electromagnetic unit such that the element contained in the second chamber moves in a direction of the device determined by the electromagnetic field and fluidly communicates the first and second chambers.

Mixing and/or reconstitution system and respective method

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L-L-L-L-Y&#x2014;Rgroups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L-L-L-Y&#x2014;R, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist. 

Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y&#x2014;R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), 

Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists

Compounds as peptidic GLP1/glucagon/GIP receptor agonists

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

Dual GLP-1/glucagon receptor agonists derived from exendin-4

The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Dual GLP-1/GIP receptor agonists

Growing community of inventors

Frankfurt am Main, Germany

Dieter Kadereit